Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10293743 | 0.77 | NOS3 (0.42) | NOS3NOS1NOS2HTR5A | |
| Carbamic Acid SCHEMBL6382077 | 0.74 | NOS3 (0.42) | NOS3NOS1NOS2HTR5AMEN1 | |
| SCHEMBL6306575 | 0.69 | ANPEP (0.36) | NOS3NOS1NOS2ANPEPMEN1 | |
| SCHEMBL11411069 | 0.63 | POLB (0.40) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL8309094 | 0.61 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL10293439 | 0.61 | PRCP (0.32) | NOS3NOS1NOS2 | |
| Water SCHEMBL6608061 | 0.59 | MAOA (0.32) | — | |
| SCHEMBL21818905 | 0.58 | MEN1 (0.40) | ANPEPMEN1KMT2A | |
| SCHEMBL5542657 | 0.58 | NOS3 (0.40) | NOS3NOS1NOS2AADATMEN1 | |
| SCHEMBL17178589 | 0.58 | KDM1A (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001901-B2 | Tetrazolylpropionamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082568-A1 | Central nervous system disorders; Alzheimer's disease | APP, APBA1, DNPEP | NOS3 1237/4885NOS1 1508/4885NOS2 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.